title: Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
abstract: BACKGROUND
  Although the eradication of Helicobacter pylori infection benefits patients with gastric or duodenal ulcers, the value of eradicating the infection in the patients with functional dyspepsia (FD) remains controversial.
  
  
  OBJECTIVE
  To determine whether eradicating H. pylori can prevent the subsequent development of ulcers or relieve the symptoms of functional dyspepsia patients.
  
  
  METHODS
  In a double-blind, placebo-controlled trial, 161 patients infected with H. pylori who had functional dyspepsia were randomly assigned to 7 days of treatment with a lansoprazole-based triple therapy or placebo and then followed for 1 year. The main outcome measures were the development of peptic ulcers and the resolution of symptoms.
  
  
  RESULTS
  H. pylori was eradicated in 63 out of 81 patients (78%) in the treatment group and none of the 80 patients (0%) in the placebo group. During the follow-up period, two patients in the treatment group and six patients in the placebo group developed peptic ulcers at repeat endoscopy (2.5% vs. 7.5%; 95% CI: -12 to 2). The reduction in ulcer rates was statistically significant in the 'ulcer-like' sub-group (0% vs. 16.7%; 95% CI: -32 to -2), but not in the 'dysmotility-like' and 'unclassifiable' sub-groups. Regarding symptom response, the resolution rates of symptoms were similar between the treatment and placebo groups (58.0% vs. 55.0%, 95% CI: -12 to 18). Additionally, no significant differences existed in the symptom responses between the treatment and control arms in each of the dyspepsia sub-groups.
  
  
  CONCLUSIONS
  Eradicating H. pylori can prevent the subsequent development of peptic ulcers in the patients with 'ulcer-like' functional dyspepsia. However, this approach does not significantly reduce the symptoms of functional dyspepsia patients.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Taiwan, Republic of China.
authors.forename: P I
authors.initials: PI
authors.lastname: Hsu
authors.forename: K H
authors.initials: KH
authors.lastname: Lai
authors.forename: H H
authors.initials: HH
authors.lastname: Tseng
authors.forename: G H
authors.initials: GH
authors.lastname: Lo
authors.forename: C C
authors.initials: CC
authors.lastname: Lo
authors.forename: C K
authors.initials: CK
authors.lastname: Lin
authors.forename: J S
authors.initials: JS
authors.lastname: Cheng
authors.forename: H H
authors.initials: HH
authors.lastname: Chan
authors.forename: M K
authors.initials: MK
authors.lastname: Ku
authors.forename: N J
authors.initials: NJ
authors.lastname: Peng
authors.forename: E J
authors.initials: EJ
authors.lastname: Chien
authors.forename: W
authors.initials: W
authors.lastname: Chen
authors.forename: P N
authors.initials: PN
authors.lastname: Hsu
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000209:etiology / Q000517:prevention & control*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole